Warning: file_get_contents(http://tehnika-news.ru/shells.txt): failed to open stream: Connection refused in /var/sites/p/paperbomb.com/public_html/meds2/1/index.php on line 2
besponsa nejm

besponsa nejm

Перейти к контенту

Главное меню:

Разное
besponsa nejm
Inotuzumab Ozogamicin versus Standard Therapy - nejm.org, Besponsa (Inotuzumab Ozogamicin) | Lymphoma News Today, BESPONSA® Approved in the EU for Adult Patients with , BESPONSA® granted NICE reassessment: Pfizer responds, BESPONSA® Approved in the EU for Adult - webwire.com, BESPONSA® Approved in the EU for Adult Patients with , , , .
Disclaimer: Lymphoma News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.. nejm 医学前沿 The authorized source of trusted medical research and education for the Chinese-language medical community. The New England Journal of Medicine. Besponsa (inotuzumab ozogamicin, previously CMC-544) is an approved therapy developed by Pfizer to treat adults with B-cell precursor acute lymphoblastic leukemia (ALL) whose disease has relapsed or who did not respond to standard therapy..
Pfizer Inc. (NYSE:PFE) today announced that the European Commission has approved BESPONSA® (inotuzumab ozogamicin) as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL). This indication includes treatment of adults. Pfizer has commented on the successful appeal hearing which saw BESPONSA® q (inotuzumab ozogamicin) granted reassessment by NICE as a treatment for adults with relapsed or refractory (R/R) CD22-positive B-cell precursor acute lymphoblastic leukaemia (ALL).. BESPONSA® Approved in the EU for Adult Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia. Results from the trial were published in The New England Journal of Medicine in June 2016. In the U.S., BESPONSA received Breakthrough Therapy designation from the Food and Drug Administration (FDA) in October 2015 for ALL.. . .
 
Copyright 2019. All rights reserved.
Назад к содержимому | Назад к главному меню